ecopipam

Ecopipam (UNII-0X748O646K) is a potent, selective, and orally active antagonist of dopamine D1 D5 receptors, with Kis of 1.2 nM and 2.0 nM, respectively. Ecopipam demonstrates more than 40-fold selectivity over D2, D4, 5-HT, and α2a receptors (Ki=0.98, 5.52, 0.08, and 0.73 μM, respectively). It is used in research on schizophrenia and obesity.

Ecopipam (SCH 39166) hydrobromide is a highly potent, specific, and orally active dopamine D1 D5 receptor antagonist with K i values of 1.2 nM for D1 and 2.0 nM for D5 receptors. It shows over 40-fold greater selectivity for D1 D5 over D2, D4, 5-HT, and α2a receptors, with K i values of 0.98, 5.52, 0.08, and 0.73 μM, respectively, and is relevant for schizophrenia and obesity research.